Nektar Therapeutics NKTR Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's other income (expense)?
- Nektar Therapeutics (NKTR) reported other income (expense) of -$4.04M in Q1 2026.
- How has Nektar Therapeutics's other income (expense) changed year-over-year?
- Nektar Therapeutics's other income (expense) decreased by 120.1% year-over-year, from -$1.83M to -$4.04M.
- What is the long-term trend for Nektar Therapeutics's other income (expense)?
- Over 3 years (2021 to 2025), Nektar Therapeutics's other income (expense) has grown at a -41.6% compound annual growth rate (CAGR), from -$77.18M to -$15.39M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.